Renal-Cell Carcinoma

Immune Checkpoint Inhibitor plus VEGFR Inhibitor Combo Outperforms Sunitinib in Renal-Cell Carcinoma

Phoebe Starr

April 2018, Vol 8, No 4 - GU Cancers Symposium Highlights, Renal-Cell Carcinoma

Progression-free survival (PFS) was extended by 3.5 months with first-line atezolizumab (Tecentriq) plus bevacizumab (Avastin) in patients with metastatic renal-cell carcinoma (RCC) versus standard-of-care sunitinib (Sutent) in the phase 3 IMmotion151 clinical trial presented at the 2018 Genitourinary Cancers Symposium. The PFS benefit of the combination of an immune checkpoint inhibitor and a vascular endothelial growth factor receptor (VEGFR) inhibitor was longer in patients with PD-L1–positive tumors. In addition, atezolizumab plus bevacizumab had an improved side-effect profile versus sunitinib. [ Read More ]

Practice-Changing: Nivolumab plus Ipilimumab Beat Sunitinib as First-Line Treatment for Metastatic RCC

Phoebe Starr

November 2017, Vol 7, No 11 - ESMO Highlights, Renal-Cell Carcinoma

Madrid, Spain—The combination of nivolumab (Opdivo) plus ipilimu­mab (Yervoy) improved overall response rates (ORRs), progression-free survival (PFS), and overall survival (OS) in patients with intermediate- and poor-risk metastatic renal-cell carcinoma (RCC) compared with sunitinib in the CheckMate-214 study. These results were presented at the 2017 European Society for Medical Oncology Congress. [ Read More ]